Paliperidone Palmitate Flexible Dosing in Schizophrenia (PALMFlexS)
A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics
Sponsor: Janssen-Cilag International NV
Listed as NCT01281527, this PHASE3 trial focuses on Schizophrenia and remains completed. Sponsored by Janssen-Cilag International NV, it has been updated 7 times since 2010, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen-Cilag International NV
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Alcorcón, Spain , Alicante, Spain , Almada, Portugal , Angra do Heroísmo, Portugal , Ankara, Turkey (Türkiye) , Arta, Greece , Athens, Greece , Bad Saarow, Germany , Bar-le-Duc, France and 117 more locations